During the recent 2025 Zhongshan Investment Promotion Conference, Zhongshan's Torch Development Zone secured a batch of key projects including Sansure Hygene's production expansion project.

Sansure Hygene is a wholly-owned subsidiary of Sansure Biotech. Since its establishment in 2008, Sansure Biotech has evolved into an integrated platform enterprise encompassing research and development, manufacturing and sales of diagnostic reagents and instruments, alongside medical laboratory services and biopharmaceuticals. Its products and services now span over 160 countries and regions worldwide.

For this production expansion project, Sansure Biotech aims to accelerate the commercialization of innovative achievements by establishing intelligent, large-scale new production lines, further expanding and strengthening its presence in Zhongshan.

On the same day, the Shenzhen Changwei Technology project, which plans to invest 500 million yuan in TDZ, will focus on the research and development of semiconductor power devices and silicon semiconductor manufacturing. It is expected to commence production within one and a half years, targeting an annual output value of 600 million yuan.

"The business environment in Zhongshan has exceeded our expectations, with the government providing enthusiastic and efficient services that have solidified our confidence in establishing operations here," said Wu Junjie, general manager of Shenzhen Changwei Technology.